Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment

By Orringer Carl E  

Clinical Lipidology, Vol. 8, Iss. 1, 2013-02 ,pp. : 69-79

Future Medicine

Access to resources Recommend Favorite

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients

By Liem A. H.   van de Woestijne A. P.   Roeters van Lennep H. W. O.   Zwinderman A. H.   van der Steeg W. A.   Jukema J. W.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 359-364

Informa Healthcare

Access to resources Recommend Favorite

Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol

By Bergheanu S. C.   Van Tol A.   Dallinga-Thie G. M.   Liem A.   Dunselman P. H. J.   Van Der Bom J. G.   Jukema J. W.  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2235-2240

Informa Healthcare

Access to resources Recommend Favorite

Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes

By Niemi Jaakko   Makinen Ville-Petteri   Heikkonen Jukka   Tenkanen Leena   Hiltunen Yrjo   Hannuksela Minna   Jauhiainen Matti   Forsblom Carol   Taskinen Marja-Riitta   Kesaniemi Y. Antero   Savolainen Markku   Kaski Kimmo   Groop Per-Henrik   Kovanen Petri   Ala-Korpela Mika  

Annals of Medicine, Vol. 41, Iss. 6, 2009-01 ,pp. : 451-461

Informa Healthcare

Access to resources Recommend Favorite

Measurement of Low‐Density Lipoprotein Cholesterol in Assessment and Management of Cardiovascular Disease Risk

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 1, 2014-07 ,pp. : 20-22

John Wiley & Sons Inc

Access to resources Recommend Favorite